Lipocine announces supply and distribution agreement with pharmalink to commercialize tlando® in the gulf cooperation council (gcc) countries

Salt lake city , oct. 8, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced an exclusive supply and distribution agreement with pharmalink https://pharmalink.ae/ to commercialize tlando®, its oral testosterone replacement therapy, in the gulf cooperation council (gcc) countries consisting of saudi arabia, kuwait, the united arab emirates (uae), qatar, bahrain, and oman.  under the terms of the agreement, lipocine received an upfront payment from pharmalink and, upon marketing authorizations (ma) in individual gcc countries, lipocine will provide tlando drug product to pharmalink at an agreed transfer price.
LPCN Ratings Summary
LPCN Quant Ranking